We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

ROCHE DIAGNOSTICS CORP

Roche Diagnostics Corporation is the North American headquarters of Roche Diagnostics, a global leader in diagnostics... read more Featured Products: More products

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Cardiac Biomarker Increase Associated with Higher Risk of Heart Disease

By LabMedica International staff writers
Posted on 30 Jun 2016
Print article
Image: The Elecsys 2010 immunology analyzer (Photo courtesy of Roche Diagnostics).
Image: The Elecsys 2010 immunology analyzer (Photo courtesy of Roche Diagnostics).
High-sensitivity cardiac troponin T (hs-cTnT), a protein that can be measured via a blood test, is a biomarker of cardiovascular risk and cardiac troponin is critical to the clinical diagnosis of heart attack, particularly among symptomatic persons with chest pain.

Detectable concentrations of high-sensitivity troponin, which indicate cardiomyocyte cell damage or death, are known to be present in a substantial proportion of asymptomatic adults without any history of cardiovascular disease; however, little is known about the implications of temporal change in hs-cTnT.

Scientists at the Johns Hopkins Bloomberg School of Public Health (Baltimore, MD, USA) and their colleagues performed a prospective observational cohort study, from January 1, 1990, to December 31, 2011, which included 8,838 biracial participants who were initially free of coronary heart disease (CHD) and heart failure (HF) and who had hs-cTnT measured twice, six years apart. Data analysis was performed from October 28, 2014, to March 9, 2016.

The first hs-cTnT level was measured in stored serum samples from visit two in 2012-2013 using a sandwich immunoassay method with a Roche Elecsys 2010 Analyzer (Roche Diagnostics, Indianapolis, IN, USA). The second hs-cTnT level was measured in stored supernatant plasma samples from visit four in 2010 using an electrochemiluminescence immunoassay implemented on a Roche Cobas e411 analyzer. Other tests included highly sensitive C-reactive protein, serum creatinine, and N-terminal pro–brain natriuretic peptide (NT-proBN).

Of the 8,838 participants (mean age, 56 years; 5,215 female (59.0%); 1,891 black (21.4%) there were 1,157 CHD events, 965 HF events, and 1,813 deaths overall. Incident detectable hs-cTnT, baseline, less than 0.005 ng/mL; follow-up, greater than 0.005 ng/mL, was independently associated with subsequent CHD, HF and death relative to an hs-cTnT level less than 0.005 ng/mL at both visits. Individuals with the most marked hs-cTnT increases, those whose baseline was less than 0.005 ng/mL but the follow-up was equal to or greater than 0.014 ng/mL, had significantly increased risks for CHD, HF and death.

The authors concluded that temporal increases in hs-cTnT, is suggestive of progressive myocardial damage, and are independently associated with incident CHD, death, and, above all, HF. Serial determination of hs-cTnT trajectory adds clinically relevant information to baseline testing and may be useful in prognostic assessments and the targeting of prevention strategies to high-risk individuals, especially among persons with stage A or B HF. The study was published on June 8, 2016, in the journal JAMA Cardiology.

Related Links:
Johns Hopkins Bloomberg School of Public Health
Roche Diagnostics
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.